SCPHscPharmaceuticals Inc

$0.00
$0.00
(0.00%)
Today
Updated:
Reported EarningsAug 7
Mkt Cap$304.36M
Vol10.9M
News
all
press releases
MannKind’s $360M scPharma Deal Splits Analysts — Retail Traders Call It ‘Bizarro Territory’ But Stay Bullish
The deal hands MannKind access to scPharma’s Furoscix heart and kidney therapy, a product with a U.S. market potential estimated at over $10 billion.
Stocktwits
News Placeholder
More News
News Placeholder
MannKind Corporation to Acquire scPharmaceuticals: More Details Inside
The transaction is expected to close in the fourth quarter of 2025, subject to necessary approvals.
Stocktwits
News Placeholder
scPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Lags Revenue Estimates
scPharmaceuticals (SCPH) delivered earnings and revenue surprises of -13.33% and -2.19%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Cytek Biosciences, Inc. (CTKB) Beats Q2 Earnings Estimates
Cytek Biosciences (CTKB) delivered earnings and revenue surprises of +150.00% and -3.30%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?
scPharmaceuticals (SCPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks
News Placeholder
ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates
Zacks
News Placeholder
Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates
chainwire
<
...
1
>

Advertisement|Remove ads.